FILER:  For May 20, 2003

                    COMPANY DATA:

COMPANY CONFORMED NAME: MEDISCIENCE TECHNOLOGY CORP
CENTRAL INDEX KEY:         0000064647

STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
[3841]

IRS NUMBER:  221937826
STATE OF INCORPORATION: NJ
FISCAL YEAR END: 0228

FILING VALUES:
                  FORM TYPE:                NT 10-K
                  SEC ACT:
                  SEC FILE NUMBER: 000-07405
                  FILM NUMBER:      643187

BUSINESS ADDRESS:
                  STREET 1:                 1235 FOLKESTONE WAY
                  CITY:                     CHERRY HILL
                  STATE:                    NJ
                  ZIP:                      08034
                  BUSINESS PHONE:   8564287952 / METPK@aol.com

MAIL ADDRESS:
                  STREET 1:                 1235 FOLKESTONE WAY
                  CITY:                     CHERRY HILL
                  STATE:                    NJ
                  ZIP:                      08034

FORMER COMPANY:
                  FORMER CONFORMED NAME:    CARDIAC TECHNIQUES INC
                  DATE OF NAME CHANGE:      19730920









                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 12b-25

                         Commission File Number 33-51218
      --------------------------------------------------------------------


                           NOTIFICATION OF LATE FILING


(Check One):   [X] Form 10-K    [_] Form 11-K    [_] Form 20-F    [X] Form 10-Q
               [_] Form N-SAR

                   For Period Ended:  February 28, 2003

   [x]  Transition Report on Form 10-K

   [_]  Transition Report on Form 20-F

   [_]  Transition Report on Form 11-K

   [_]  Transition Report on Form 10-Q

   [_]  Transition Report on Form N-SAR

        For the Transition Period Ended: February 28, 2003

Read attached instruction sheet before preparing form.  Please print or
type.

Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify
the item(s) to which the notification relates:













                                     PART I
                             REGISTRANT INFORMATION

                          MEDISCIENCE TECHNOLOGY CORP.

- -----------------------------------------------------------------------
Full Name of Registrant



- -----------------------------------------------------------------------
Former Name if Applicable


1235 Folkestone Way
- -----------------------------------------------------------------------
Address of Principal Executive Office (Street and Number)


Cherry Hill, NJ  08034
- -----------------------------------------------------------------------
City, State and Zip Code























                                     PART II
                             RULE 12b-25(b) AND (c)

     If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check box if appropriate.)

     |    (a) The reasons described in reasonable detail in Part III of this
     |         form could not be eliminated without unreasonable effort or
     |         expense;
     |
     |    (b) The subject annual report, semi-annual report, transition report
     |         on Form 10-K, Form 20-F, Form 11-K or Form N-SAR, or portion
     |         thereof will be filed on or before the 15th calendar day
                            -------------------------------------------
     |         following the prescribed due date; or the subject quarterly
     |         report or transition report on Form 10-Q, or portion thereof will
     |         be filed on or before the fifth calendar day following the
     |         prescribed due date; and
     |
     |    (c) The accountant's statement or other exhibit required by Rule
     |         12b-25(c) has been attached if applicable.


                                    PART III
                                    NARRATIVE

State below in reasonable detail why the Form 10-K, 11-K, 20-F 10-Q, N-SAR or
                                         ---------
the transition report portion thereof could not be filed within the prescribed
time period. (Attach extra sheets if needed.)

The registrant is a development stage company which, at present, has only two
non-research full time employees, its Chairman of the Board CEO, Peter Katevatis
and Michael Engelhart Pres/COO. In the period since March 1, 2002, Mr. Katevatis
has devoted substantially all of his time and efforts to the negotiation and
supervision of existing and prospective business relationships which are of
crucial importance to the registrant's future, including the orderly transition
of the audit function to its contracted auditors Parent Randolph LLC, from prior
auditors Arthur Anderson LLC, additionally the registrant is mindful and
properly implementing the Sarbanes-Oxley present-day SEC corporate governance
obligations. Despite this prioritization of Mr. Katevatis' time, the registrant
expects to be able to file its quarterly Report on Form 10-K for fiscal year
                                                   -------------------------
February 28, 2003 on or prior to June 15, 2003.
- -----------------

     The delay in filing the registrant's quarterly Report on Form 10-K is not
due to any change in or disagreement with the registrant's accountants on
financial statement or other required "material" disclosures now governed by
Sarbanes-Oxley.




                                     PART IV
                                OTHER INFORMATION

(1)  Name and telephone number of person to contact in regard to this
     notification

         Peter Katevatis              (856) 428-7952 or (215) 763- 4803
     ---------------------------------------------------------------------
             (Name)                      (Area Code) (Telephone Number)

(2)  Have all other periodic reports required under Section 13 or 15(d) of the
     Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
     of 1940 during the preceding 12 months or for such shorter period that the
     registrant was required to file such report(s) been filed? If the answer is
     no, identify report(s).
                             [X] Yes [_] No

(3)  Is it anticipated that any significant change in results of operations from
     the corresponding period for the last fiscal year will be reflected by the
     earnings statements to be included in the subject report or portion
     thereof?
                             [_] Yes [X] No

If so: attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.

                          Mediscience Technology Corp.
- --------------------------------------------------------------------------------
                  (Name of Registrant as Specified in Charter)

Has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.


Date May 20, 2003                 By /s/ Peter Katevatis
- --------------------------           -------------------------------------------
                                     Peter Katevatis, Chairman of the Board, CEO

     INSTRUCTION: The form may be signed by an executive officer of the
     Registrant or by any other duly authorized representative. The name and
     title of the person signing the form shall be typed or printed beneath the
     signature. If the statement is signed on behalf of the registrant by an






     authorized representative (other than an executive officer), evidence of
     the representative's authority to sign on behalf of the registrant shall be
     filed with the form.


                                    ATTENTION

     Intentional misstatements or omissions of fact constitute Federal Criminal
Violations (see 18 U.S.C. 1001).


                              GENERAL INSTRUCTIONS

     1. This form is required by Rule 12b-25 of the General Rules and
Regulations under the Securities Exchange Act of 1934.

     2. One signed original and four conformed copies of this form and
amendments thereto must be completed and filed with the Securities and Exchange
Commission, Washington, D.C. 20549, in accordance with Rule 0-3 of the General
Rules and Regulations under the Act. The information contained in or filed with
the form will be made a matter of public record in the Commission files.

     3. A manually signed copy of the form and amendments thereto shall be filed
with each national securities exchange on which any class of securities of the
registrant is registered.

     4. Amendments to the notifications must also be filed on Form 12b-25 but
need not restate information that has been correctly furnished. The form shall
be clearly identified as an amended notification.

     5. ELECTRONIC FILERS. This form shall not be used by electronic filers
unable to timely file a report solely due to electronic difficulties. Filers
unable to submit a report within the time period prescribed due to difficulties
in electronic filing should comply with either Rule 201 or Rule 202 of
Regulation S-T or apply for an adjustment in filing date pursuant to Rule 13(b)
of Regulation S-T.